Zirconium (89Zr) girentuximabum senvedoxamum

Cohort 7 of the clinical trial of HDP-101 in multiple myeloma safe and well tolerated Cohort 8 expected to start soon Clinical development of the second ADC program HDP-102 in patients with non-Hodgkin lymphoma (NHL) has started Amendment of contract with HealthCare Royalty; payment of USD 20 million significantly extends cash reach Ladenburg, Germany, 24 April 2025 - Heidelberg Pharma AG (FSE: HPHA) today reported on the first three months of fiscal year 2025 (1 December 2024 – 28 February 2025) and the Group’s financial figures. Professor Andreas Pahl, Chief Executive Officer of Heidelberg Pharma AG, commented: “We are pleased that our lead ATAC candidate, HDP-101, has again proven to be safe and well tolerated in cohort 7 at a dose of 112.50 µg/kg. We have not yet reached the maximum tolerated dose and are continuing the dose escalation as planned. This supports that we are developing an ATAC with an attractive therapeutic window. Particularly encouraging is the persistently stable condition of a patient with complete remission. All this allows us to be very optimistic about the start of cohort 8. In addition, we are reaching the next milestone in our pipeline – clinical testing of our second ATAC program HDP-102 has started.” Walter Miller, Chief Financial Officer of Heidelberg Pharma AG, added: “Not only are our clinical projects making promising progress, but our financing activities have also been extremely successful. As a result of the amendment of the license agreement with HealthCare Royalty, we received a further payment of USD 20 million at the beginning of March. This and an expected payment of USD 70 million upon market approval of Telix’ TLX250-CDx extend our cash reach into 2027 based on current planning. We are pleased with this solid financial footing as we advance the development of our product portfolio.” HDP-101 (BCMA ATAC) development program: The Amanitin-based ADC candidate HDP-101 is being evaluated in a Phase I/IIa clinical trial for the treatment of relapsed or refractory multiple myeloma. The first seven patient cohorts and dose levels have been completed. After completion of cohort 7, the Safety Review Committee (SRC) concluded that the 112.50 µg/kg dose used is safe and well tolerated and that the study can continue with cohort 8 at a dose of 140 µg/kg. Analogous to the dosing regimen of cohort 7, patients in cohort 8 will also be dosed in two different arms. As long as patients in cohort 7 do not progress, they will continue to be treated with the previous dose level. The analysis of the data is ongoing. The presentation of new clinical data is planned for the EHA Congress, a conference of the European Hematology Association, in Milan, Italy, in mid-June. The study has shown very encouraging results so far, including a complete remission in a patient from cohort 5 who had been heavily pretreated with different therapies and was then treated continuously with HDP-101 alone. In addition, several patients showed promising biological activity and objective improvements, which underscores the potential of HDP-101 as a treatment option for patients with multiple myeloma. Development program HDP-102: HDP-102 is an ATAC targeting CD37 that is expressed on B-cell lymphoma cells. Heidelberg Pharma plans to develop HDP-102 for non-Hodgkin lymphoma (NHL). With over 550,000 new cases diagnosed each year worldwide, NHL is one of the more common types of cancer. Heidelberg Pharma has received all the necessary approvals to start the clinical trial and expects the dosing of the first patient shortly. The trial will be conducted in the Republic of Moldova, Israel and selected EU countries. New preclinical data were presented at the American Association for Cancer Research (AACR) 2024 Annual Meeting. The candidate showed in-vivo excellent anti-tumor efficacy and good tolerability after a single administration. TLX250-CDx - Partnered radio-pharmaceutical program on the road to market approval In December 2024, the Australian partner Telix Pharmaceuticals Limited, Melbourne, (Telix) completed the submission of the revised Biologics License Application (BLA) for its PET imaging agent TLX250-CDx to the US Food and Drug Administration (FDA). On 26 February 2025, Telix announced that the FDA had accepted the BLA for TLX250-CDx, granted a Priority Review, and provided a Prescription Drug User Fee Act (PDUFA) date of 27 August 2025. Amendment of the royalty purchase agreement with HealthCare Royalty secures earlier payment: Heidelberg Pharma and Healthcare Royalty (HCRx) announced on 13 March 2025 that they had signed an amendment to the original license agreement dated March 2024. Heidelberg Pharma received an immediate payment of USD 20 million upon signing of the agreement. In return, the sales-related milestone of USD 15 million for 2025 no longer applies due to the later potential launch of TLX250-CDx and the originally agreed payment of USD 75 million upon approval of TLX250-CDx by the FDA is reduced to USD 70 million, with further potential reductions if FDA approval occurs after the end of 2025. The basis of consolidation as of the reporting date comprises Heidelberg Pharma AG and Heidelberg Pharma Research GmbH and the two companies established in the previous year, HDP G250 AG & Co. KG and HDP G250 Beteiligungs GmbH. These two companies are affiliated below the parent company Heidelberg Pharma AG, are not operationally active and are each fully consolidated. The reporting period referred to below concerns the period from 1 December 2024 to 28 February 2025 (Q1 2025). In the first three months of fiscal year 2025, the Group generated sales revenue and other income totaling EUR 2.9 million (previous year: EUR 1.9 million). As in the previous year, this includes EUR 1.3 million sales revenue, which in turn largely consists of deferred income in both years. Other income increased by EUR 1.6 million compared to the previous year (EUR 0.6 million) and resulted primarily from a milestone payment in connection with the sale of a minority interest in 2023. Operating expenses, including depreciation, amounted to EUR 9.0 million in the reporting period (previous year: EUR 6.6 million). Cost of sales amounted to EUR 44 thousand and were thus roughly in line with the previous year's figure (EUR 30 thousand). Research and development costs increased as planned to EUR 6.6 million compared to EUR 5.1 million in the same quarter of the previous year and, at 73% of operating expenses, represented the largest cost item. Both periods were characterized by the cost-intensive external manufacturing for the ADC projects and the ongoing clinical study with HDP-101, and this year's period was also influenced by the preparation of the clinical study with HDP-102. Administrative expenses increased to EUR 1.6 million in the first three months of 2025 compared to the prior-year period (EUR 1.2 million). These include, among other things, the costs of holding activities and the stock exchange listing. Other expenses for business development, marketing and everything else increased from EUR 0.2 million in the previous year to EUR 0.7 million, in particular due to foreign currency valuations. The Heidelberg Pharma Group´s net loss increased for the first three months of the fiscal year to EUR 5.9 million compared to the previous year (EUR 4.5 million) as planned. Basic earnings per share based on the weighted average number of shares issued during the reporting period decreased from EUR -0.10 in the previous year to EUR -0.13 in the past quarter as a result of the increased loss. Total assets as of 28 February 2025 amounted to EUR 52.8 million and was below the comparable figure as of 30 November 2024 (EUR 60.7 million) due to the loss for the period as well as reduced liabilities and the associated lower cash. At EUR 25.1 million, equity was also below the figure at the end of the 2024 fiscal year (EUR 30.9 million). This corresponds to an equity ratio of 47.5% (30 November 2024: 50.8%). No corporate actions were carried out during the reporting period. The capital stock of Heidelberg Pharma AG thus remained unchanged at EUR 46,604,977, divided into 46,604,977 no par value bearer shares. At the end of the fiscal quarter, cash amounted to EUR 20.7 million (30 November 2024: EUR 29.4 million). Heidelberg Pharma thus recorded an average cash outflow of EUR 2.9 million per month in the first quarter of the fiscal year (previous year: EUR 3.6 million). Financial outlook for 2025 The Executive Management Board expects the Heidelberg Pharma Group to generate between EUR 9.0 million and EUR 11.0 million in sales revenue and other income in the 2025 fiscal year. If income and expenses develop as anticipated, the change in cash funds in the 2025 fiscal year for Heidelberg Pharma AG’s business operations is expected to improve significantly compared to 2024. The expected cash inflow will be between EUR 50.0 million and EUR 55.0 million in total due to a further HCRx payment. Operating expenses in 2025 are expected to be between EUR 40.0 million and EUR 45.0 million if business develops as planned, and thus roughly at the level of the 2024 reporting year (EUR 32.6 million). An operating result of between EUR -30.0 million and EUR -35.0 million is expected for 2025 (2024: EUR -20.7 million). Based on the current budget, and taking into account an additional expected payment of USD 70.0 million (less transaction costs) from HealthCare Royalty, the Group is funded into 2027. A conference call on this interim management statement will not take place. The complete figures for the interim financial statements can be downloaded from http://www.heidelberg-pharma.com/ ”Press & Investors > Announcements > Financial Reports > Interim statement on the first three months of 2025”. Key figures for the Heidelberg Pharma Group (unaudited) In EUR thsd. Q1 20251 EUR thsd. Q1 20241 EUR thsd. Earnings Sales revenue 1,270 1,267 Other income 1,603 592 Operating expenses (8,991) (6,566) of which research and development costs (6,610) (5,073) Operating result (6,118) (4,707) Earnings before tax (5,938) (4,445) Net loss for the period / Comprehensive income (5,938) (4,494) Earnings per share in EUR (basic) (0.13) (0.10) Balance sheet as of the end of the period Total assets 52,805 61,666 Cash 20,678 32,650 Equity 25,063 45,114 Equity ratio2 in % 47.5 73.2 Cash flow statement Cash flow from operating activities (8,584) (10,748) Cash flow from investing activities (121) (42) Cash flow from financing activities (31) (29) Employees (number) Employees as of the end of the period3 116 111 Full-time equivalents as of the end of the period3 105 98 1 The reporting period begins on 1 December and ends on 28/29 February. 2 Equity / total assets 3 Including members of the Executive Management Board Rounding of exact figures may result in differences.

MELBOURNE, Australia and INDIANAPOLIS, April 22, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today provides an update on its commercial and operational performance for the quarter ended 31 March 2025 (Q1 2025). All figures are in $US unless stated otherwise. Strong Q1 2025 revenue growth Q1 2025 unaudited revenue of approximately $186 million represents an increase of 62% over the prior year corresponding quarter (Q1 2024: $115M) and a quarter-over-quarter increase of 31% (Q4 2024: $142 million) and includes: $151 million from global sales of Illuccix®, up 35% over the prior year corresponding quarter (Q1 2024: $112 million) and a quarter-over-quarter increase of 9% (Q4 2024: $139 million).$33 million from RLS Radiopharmacies (RLS) since the acquisition completed on 27 January 20251. FY 2025 guidance reaffirmed Telix confirms FY 2025 revenue guidance of $770 million to $800 million2.Guidance reflects revenue from Illuccix® sales in jurisdictions with a marketing authorization, and 11 months of revenue from RLS1,3.Revenue guidance is expected to be updated at the appropriate time, following and subject to reimbursement for Gozellix® in the United States (U.S.) and Illuccix® in ex-U.S. markets.Telix confirms research and development (R&D) expenditure guidance, expecting a year-over-year increased investment range for FY 2025 of 20% to 25% compared to FY 2024. Q1 2025 commentary and recent highlights Telix Managing Director and Group CEO, Dr. Christian Behrenbruch, stated, “Illuccix has continued its momentum, gaining market share and maintaining price stability in a competitive landscape. Telix is the only company with two FDA4-approved PSMA-PET5 imaging agents – Illuccix and Gozellix – enabling us to broaden patient reach and maximize choice for our customers. The expansion of our commercial portfolio and launches of Illuccix into new international markets provides a foundation to diversify and grow revenue globally, while we continue to deliver on multiple catalysts in our pipeline. This quarter also includes the first two months of revenue from RLS since completion of our acquisition, highlighting its potential as a platform to drive further growth. This strategic acquisition has significantly expanded our manufacturing footprint in the U.S., which we believe is an increasingly important consideration amid changing global trade dynamics.” Therapeutics business ProstACT™ Global, the Phase 3 trial of TLX591 (177Lu-rosopatamab tetraxetan), Telix’s prostate cancer therapy candidate, continues to recruit and remains on track to deliver a Part 1 readout (safety and dosimetry) in H1 2025.IPAX-Linz, a Phase 2 investigator-initiated trial of TLX101 (131I-iodofalan, or 131I-IPA), Telix’s brain cancer therapy candidate, reported positive preliminary results. Early efficacy from IPAX-1 was substantiated and TLX101 was found to be well tolerated in combination with external beam radiation therapy. No serious adverse events were reported in patients at first or second recurrence with high-grade gliomas (HGG), including glioblastoma, often after multiple resections6.Following consultations with the FDA, the Company remains on track to submit Investigational New Drug (IND) applications to enable pivotal trials for TLX101 and Telix’s kidney cancer therapy candidate (TLX250, 177Lu-DOTA-girentuximab) to commence this year, subject to regulatory approval.The first patient was dosed in the Phase 1 ZOLAR7 trial of TLX300-CDx (89Zr-olaratumab), which aims to validate the use of olaratumab, an antibody exclusively licensed from Eli Lilly and Company (Lilly), as a potential treatment for advanced, metastatic soft tissue sarcoma.Telix completed the acquisition of a suite of clinically validated FAP8-targeting therapeutic and precision medicine (diagnostic) radiopharmaceutical candidates. Telix has added the lead FAP-targeting therapeutic compound to its pipeline under the designation TLX400.Telix acquired the therapeutics assets of antibody engineering company ImaginAb, Inc. The transaction included a pipeline of next-generation therapeutic candidates, a proprietary novel biologics technology platform, and a protein engineering and discovery research facility in Los Angeles, California9, staffed by a talented team of discovery, protein engineering and radiopharmaceutical development experts who joined the Company on the ImaginAb acquisition closing.Telix announced that it has developed and validated a breakthrough generator technology for the production of lead-212 (212Pb) and successfully completed first production of this promising alpha-emitting therapeutic radioisotope10. The new generator technology, developed internally by Telix’s IsoTherapeutics team, significantly increases the amount of radioactivity, yield and shelf life compared to currently available 212Pb generators and provides an additional isotope supply for Telix’s next-generation targeted alpha therapy program. Precision Medicine business On 21 March 2025, the FDA approved the New Drug Application (NDA) for Gozellix®11, Telix’s next-generation PSMA-PET imaging agent for prostate cancer that provides a longer shelf life of up to six hours and an extended distribution radius compared to existing gallium-based imaging products.Commercial launch of Gozellix® in the U.S. is expected to commence during Q2 2025 where Telix has appointed Cardinal Health, Inc. (Cardinal Health)12 and RLS Radiopharmacies as distribution partners.Telix received a positive decision on the decentralized Marketing Authorization Application (MAA) for Illuccix® in the European Economic Area (EEA)13. Illuccix® also received MAA approval in the United Kingdom (UK) and Brazil. Country level approvals are now being implemented in the EEA, with approvals to date granted in Denmark, Ireland, Luxembourg, Malta, the Netherlands, Norway, and Sweden14.Illuccix® is now commercially available in Brazil, under the joint venture with R2PHARMA (Telix Innovations Brazil, Ltda.), and commercial launches will commence in the UK and in European markets where Illuccix® has received approval during Q2 2025.The FDA accepted the Biologics License Application (BLA) for Telix’s kidney cancer imaging candidate TLX250-CDx (Zircaix®15, 89Zr-DFO-girentuximab), granted a Priority Review, and provided a PDUFA16 goal date of 27 August 2025.The NDA for TLX101-CDx (Pixclara®15, 18F-floretyrosine or 18F-FET), Telix’s brain cancer imaging candidate, continues to progress with a PDUFA goal date of 26 April 2025. Telix Manufacturing Solutions (TMS) In April, the TMS Brussels South facility (Seneffe) received notice of its GMP accreditation, enabling first commercial radiopharmaceutical dose production.Telix reaffirms that it does not expect any material impact on its business or supply chain as a result of the international trade tariffs announced by the U.S. government on 2 April 2025 (subject to a three-month delay) or the subsequent inclusion of pharmaceuticals. Telix has an extensive U.S.-based manufacturing and distribution infrastructure, including third-party manufacturing sites and radiopharmacy partner networks, for the production and delivery of its FDA-approved products Illuccix® and Gozellix®17.Telix also notes that it does not rely on rare earth elements of the kind utilized in semi-conductor supply chains and is therefore not impacted by the recent export controls imposed by the Chinese government this month. Board renewal Telix announced new Director appointments as part of a Board succession planning and renewal process18: H Kevin McCann AO will retire as a Non-Executive Director (NED) and Board Chairman on 21 May 2025, immediately following Telix’s Annual General Meeting.Tiffany Olson will be appointed Board Chair following Mr. McCann’s retirement.Marie McDonald joined the Board as a NED, effective 3 March 2025 and, on appointment, immediately succeeded Mr. McCann as Chair of the People Committee.Anne Whitaker joined the Board as a NED, effective 7 April 2025, and was appointed as a member of the Audit and Risk Committee and the People Committee. Guidance disclaimer The stated revenue guidance is based on expected global and domestic economic conditions and is subject to known and unknown risks, uncertainties and other factors that may cause our actual results to differ materially. As such, investors are cautioned not to place undue reliance on this guidance and in particular Telix cannot guarantee a particular result. In compiling financial forecasts, a number of key variables that may have a significant impact on guidance have been identified and are listed below. Key variables that could cause actual results to differ materially include: the success and timing of research and development activities; decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; competitive developments affecting our products; the ability to successfully market new and existing products; difficulties or delays in manufacturing; trade buying patterns and fluctuations in interest and currency exchange rates; legislation, regulation, or policy that affects product production, distribution, pricing, reimbursement, access or tax; acquisitions and divestitures; research collaborations; litigation or government investigations; and Telix’s ability to protect its patents and other intellectual property. See the Legal Notices section below for additional information, risks and assumptions. About Telix Pharmaceuticals Limited Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. ARTMS, IsoTherapeutics, Lightpoint, Optimal Tracers and RLS are Telix Group companies. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX). Telix’s prostate imaging product, gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix®), has been approved by the FDA19, the Australian Therapeutic Goods Administration (TGA)20, Health Canada21, the UK Medicines and Healthcare Products Regulatory Agency (MHRA)22, by the Brazilian Health Regulatory Agency (ANVISA)23, and in multiple countries within the European Economic Area (EEA)24. Illuccix® is currently in national approval review elsewhere in the EEA following a positive decentralized procedure (DCP) opinion by the German medical regulator, BfArM25. Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection) has been approved by the FDA26. Telix’s osteomyelitis (bone infection) imaging agent, technetium-99m (99mTc) besilesomab, marketed under the brand name Scintimun®, is approved in 32 European countries and Mexico. Telix’s miniaturized surgical gamma probe, SENSEI®, for minimally invasive and robotic-assisted surgery, is registered with the FDA for use in the U.S. and has attained a Conformité Européenne (CE) Mark for use in the European Economic Area. No other Telix product has received a marketing authorization in any jurisdiction. Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and SEC filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook. Telix Investor Relations Ms. Kyahn WilliamsonTelix Pharmaceuticals LimitedSVP Investor Relations and Corporate CommunicationsEmail: kyahn.williamson@telixpharma.com Telix Investor Relations (U.S.) Annie KasparianTelix Pharmaceuticals LimitedDirector Investor Relations and Corporate CommunicationsEmail: annie.kasparian@telixpharma.com This announcement has been authorised for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board. Legal Notices You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website. The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement. This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. ©2025 Telix Pharmaceuticals Limited. Telix Pharmaceuticals, Telix Group company, and Telix product names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved. Trademark registration status may vary from country to country. ______________________________________________1 Excludes revenue contribution from Illuccix® sales.2 Refer to ASX disclosures 20 February 2025. 3 See Guidance Disclaimer for further information.4 U.S. Food and Drug Administration.5 Imaging of prostate-specific membrane antigen with positron emission tomography.6 Telix ASX disclosure 16 April 2025.7 Telix media release 1 April 2025. ClinicalTrials.gov ID: NCT06537596.8 Fibroblast activation protein.9 Telix ASX disclosure 13 January 2025.10 Telix media release 13 March 2025.11 Telix ASX disclosure 21 March 2025.12 Telix media release 8 April 2025.13 Telix ASX disclosure 17 March 2025.14 Illuccix® received marketing authorization in the UK, Brazil, Denmark, Luxembourg, Malta, the Netherlands and Norway during Q1 2025. Illuccix® received marketing authorization in Ireland and Sweden on 4 and 11 April 2025, respectively. 15 Brand name subject to final regulatory approval. 16 Prescription Drug User Fee Act.   17 Telix ASX disclosure 7 April 2025.18 Telix ASX disclosure 26 February 2025.19 Telix ASX disclosure 20 December 2021.20 Telix ASX disclosure 2 November 2021.21 Telix ASX disclosure 14 October 2022.22 Telix ASX disclosure 13 February 2025.23 Telix ASX disclosure 18 March 2025.24 Denmark, Ireland, Luxembourg, Malta, the Netherlands, Norway and Sweden at time of release.25 Telix ASX disclosure 17 January 2025.26 Telix ASX disclosure 21 March 2025.